Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Official state websites that don’t include Undetectable Equals Untransmittable details often contain misleading or ambiguous HIV language.
Some experts suggest changing treatment guidelines to include Cabenuva for those without viral suppression when other options aren’t working
The HIV attachment inhibitor led to sustained viral suppression and CD4 cell gains in people with extensive prior treatment.
All participants with detectable HIV on oral meds achieved viral suppression after switching to long-acting injectables.
People with a suppressed but detectable viral load (under 1,000) have “almost zero or negligible risk” of sexual transmission.
Broadly neutralizing antibodies may help bring about long-term remission.
A trial looked at outcomes among treatment-experienced people on suppressive antiretroviral therapy who switched to dolutegravir/lamivudine.
Using two instead of three or four drugs could potentially lead to cost savings in the billions.
HIV.gov conversations about doxyPEP, HIV PrEP and the effectiveness of U=U.
44% of children treated with two bnAbs maintained viral suppression after stopping antiretrovirals.
Untreated HIV may result in persistent immune activation and inflammation that can lead to a wide range of health problems.
Long-acting therapies are the future of HIV treatment and prevention.
Maintaining an undetectable viral load can halt progression of HIV and eliminate the risk of transmission.
The all-oral regimen maintained viral suppression in people with resistance to multiple antiretrovirals.
Individuals who maintained a low viral load without treatment had a higher rate of non-AIDS-defining conditions.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.